Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1
Authors:
- Charles CatzavelosCCCharles Catzavelos
- Joyce M. SlingerlandJSJoyce M. Slingerland
- 1 November 1998
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 52 (1-3) , 29-41
Abstract
Mitogenic and growth inhibitory signals influence the activity of a family of cyclin dependent kinases (cdks). p27 is an important cdk inhibitor, acting in G1 to inhibit cyclin-cdks. As negative growth regulators, the cdk inhibitors may function as tumor suppressors. While the p16 gene plays a tumor suppressor role in cancers, p27 gene mutations have been identified only rarely. While high levels of p27 protein are expressed in normal human mammary epithelium, loss of p27 is frequent and is of independent prognostic significance in breast cancers. Low p27 is also a poor prognostic factor in colon, gastric, esophageal, lung, and prostate carcinomas, and enhanced proteasomal degradation may underlie loss of p27 in tumor cells. Loss of p27 has not been significantly correlated with tumor proliferation in a number of studies and may reflect alterations in differentiation and adhesion-dependent growth regulation germane to oncogenesis and tumor progression. Efforts to confirm the prognostic value of p27 are under way in a number of large breast cancer studies. These studies may also indicate whether loss of p27 in association with other traditional or novel markers has greater prognostic potential than each factor alone. p27 immunostaining is inexpensive and reliable and may become part of the routine histopathologic processing of tumors in the near future. Widespread application of p27 in prognostic testing will require greater uniformity in scoring techniques and determination of the cut off levels which distinguish individuals at high and low risk of cancer recurrence and death. Finally, the greatest utility of p27 may lie in the information it sheds on the biology of aberrant growth regulation in breast cancer and the potential to use this in the generation of novel therapeutic strategies.Keywords
This publication has 77 references indexed in Scilit:
- Protein Expression of the Cell-Cycle Inhibitor p27Kip1 in Malignant MelanomaThe American Journal of Pathology, 1998
- Ras Activity Late in G 1 Phase Required for p27
kip1
Downregulation, Passage through the Restriction Point, and Entry into S Phase in Growth Factor-Stimulated NIH 3T3 FibroblastsMolecular and Cellular Biology, 1997
- Ras Links Growth Factor Signaling to the Cell Cycle Machinery via Regulation of Cyclin D1 and the Cdk Inhibitor p27KIP1Molecular and Cellular Biology, 1997
- Transforming Growth Factor β Stabilizes p15
INK4B
Protein, Increases p15
INK4B
-cdk4 Complexes, and Inhibits Cyclin D1-cdk4 Association in Human Mammary Epithelial CellsMolecular and Cellular Biology, 1997
- Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomasHuman Genetics, 1996
- Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation.Molecular Biology of the Cell, 1995
- Novel INK4 Proteins, p19 and p18, Are Specific Inhibitors of the Cyclin D-Dependent Kinases CDK4 and CDK6Molecular and Cellular Biology, 1995
- Identification of Human and Mouse p19, a Novel CDK4 and CDK6 Inhibitor with Homology to p16ink4Molecular and Cellular Biology, 1995
- Inhibition of cyclin-dependent kinases by p21.Molecular Biology of the Cell, 1995
- G1 control in mammalian cellsJournal of Cell Science, 1994